A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels
Latest Information Update: 25 Jun 2025
At a glance
- Drugs AZD 4954 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 19 Jun 2025 Planned End Date changed from 23 Jul 2026 to 4 Dec 2026.
- 19 Jun 2025 Planned primary completion date changed from 23 Jul 2026 to 4 Dec 2026.
- 19 Jun 2025 Status changed from not yet recruiting to recruiting.